{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:21:51Z","timestamp":1794345711869,"version":"4.9.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jaccas.2026.107742","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:14:40Z","timestamp":1775074480000},"page":"107742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Giant Cell Arteritis as a Form of Pembrolizumab-Associated Vascular Toxicity"],"prefix":"10.1016","volume":"31","author":[{"given":"Daichi","family":"Umemoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8466-3025","authenticated-orcid":false,"given":"Eri","family":"Iwai-Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jaccas.2026.107742_bib1","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1093\/rheumatology\/keaf172","article-title":"Immune checkpoint inhibitors-induced large vessel vasculitis: clinical characteristics and management from a European multicentre study","volume":"64","author":"Cottu","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.jaccas.2026.107742_bib2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.jaccas.2026.107742_bib3","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jaccas.2026.107742_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamaoncol.2025.4543","article-title":"Immune checkpoint inhibitor-associated cardiovascular toxic effects: International Cardio-Oncology Society Position Statement","volume":"12","author":"Herrmann","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccas.2026.107742_bib5","first-page":"E970","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7-8","key":"10.1016\/j.jaccas.2026.107742_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103589","article-title":"Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic literature review highlighting differences from the idiopathic forms","volume":"23","author":"Hysa","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.jaccas.2026.107742_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/01658107.2022.2108847","article-title":"Pembrolizumab-induced giant cell arteritis in the setting of urothelial carcinoma","volume":"47","author":"Miano","year":"2023","journal-title":"Neuroophthalmology"},{"issue":"11","key":"10.1016\/j.jaccas.2026.107742_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-246443","article-title":"Giant cell arteritis associated with PD-1 inhibition","volume":"14","author":"Couette","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"5","key":"10.1016\/j.jaccas.2026.107742_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00005792-200009000-00001","article-title":"Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients","volume":"79","author":"Gonz\u00e1lez-Gay","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaccas.2026.107742_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.803706","article-title":"Frequency of immune checkpoint inhibitor-induced vasculitides: an observational study using data from the Japanese adverse drug event report database","volume":"13","author":"Kato","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608492600896X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608492600896X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T20:32:38Z","timestamp":1794342758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266608492600896X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":10,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S266608492600896X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.107742","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Giant Cell Arteritis as a Form of Pembrolizumab-Associated Vascular Toxicity","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.107742","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"107742"}}